Pathogenesis and treatment prospects for Covid-19: a review
DOI:
https://doi.org/10.33448/rsd-v9i7.3730Keywords:
Patogênese, Tratamento farmacológico, Coronavírus.Abstract
Objective: to present the form of action and interaction of SARS-CoV-2 with human cells and describe the main studies on the treatment for Covid-19. Methodology: a review was carried out in the Science Direct-Elsevier and PubMed databases with analysis of experimental works in vitro and in vivo, review, technical notes and clinical research records. The terms used were: Coronavirus, COVID-19, SARS-CoV-2 associated with pathogenesis, clinical studies and treatment. Results: Many studies are under development to understand the pathogenesis of the virus and to seek efficient therapies to contain COVID-19, such as chloroquine, hydroxychloroquine, Arbidol, favipiravir, remdesivir, among others. Conclusion: This article reviewed the mechanisms of action of SARS-CoV-2 in order to provide information for a better understanding of the actions taken by several researchers in therapy against COVID-19. Many drugs are undergoing clinical trials to see if they can minimize the serious effects of the virus on the population.
References
Casadevall, A., & Pirofski, L. (2020). The convalescent sera option for containing COVID-19. The Journal of Clinical Investigation, 130 (4), 1545-1548.
Catella-Lawson, F. et al. (2001). Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. New England Journal of Medicine, 345 (25), 1809-1817.
Chen, C.et al. (2020). Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial. MedRxiv, 3 (17), e20037432
Chen, J. (2020). Pathogenicity and transmissibility of SARS-CoV-2 quick overview and comparison with other emerging viruses. Microbes and Infection, 22 (2), 69-71.
Chen, N. et al. (2020). Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet, 395 (10223), 507-513.
Colson, P. et al. (2020). Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. International Journal of Antimicrobial Agents, 5 (41), e105932.
Dong, L., Hu, S., & Gao, J. (2020). Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discoveries & Therapeutics, 14 (1), 58-60.
Elfiky, A. A. (2020). Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study. Life Sciences, 2020.
Fitzgerald, G. A. (2020). Misguided drug advice for COVID-19, Science, 367 (6485) e1434.
Fung, S.et al. (2020). A tug-of-war between severe acute respiratory syndrome coronavirus 2 and host antiviral defense: lessons from other pathogenic viruses. Emerging Microbes & Infections, 9 (1), 558-570.
Gao, J., Tian, Z., & Yang, X. (2020). Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Bioscience Trends, 14 (1), 72-73.
Gautret, P. et al. (2020). Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. International Journal of Antimicrobial Agents, e105949.
Han, Y., & Yang, H. (2020). The transmission and diagnosis of 2019 novel coronavirus infection disease (COVID‐19): A Chinese perspective. Journal of Medical Virology, 1-6.
Hilgenfeld, R. (2014). From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design, The FEBS journal, 281 (18), 4085-4096.
Holshue, M. L. et al. (2020). First case of 2019 novel coronavirus in the United States. New England Journal of Medicine, 382 (10), 929-936.
Huang C. et al. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 15 (395), 497-506.
Khan, S. et al. (2020). The emergence of a novel coronavirus (SARS-CoV-2), their biology and therapeutic options. Journal of Clinical Microbiology.
Li, Q. et al. (2020). Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. New England Journal of Medicine, 382 (13), 1199-1207.
Liu, C. et al. (2020). Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases. ACS Central Science, 6 (3), 315-331.
Liu, J. et al. (2020). Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discovery, 6 (1), 1-4.
Liu, J. et al. (2020). Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses SARS‐CoV, MERS‐CoV, and 2019‐nCoV. Journal of Medical Virology, 92 (5), 491-494.
Lu, R. et al. (2020). Genomic characterization and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. The Lancet, 95 (10224), 565-574.
Savarino, A., Boelaert, J.R., Cassone, A., Majori, G., & Cauda, R. (2003). Effects of chloroquine on viral infections: an old drug against today's diseases? The Lancet Infectious Diseases, 3 (11), 722-727.
Sheahan, T. P. et al. (2020). Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nature Communications, 11 (1), 1-14.
Shereen, M. A. et al. (2020). COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses. Journal of Advanced Research, 24, 91-98.
Singh, A. K. et al. (2020). Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 14 (3), 241-246.
Wang, M. et al. (2020). Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (SARS-CoV-2) in vitro. Cell research, 30 (3), 269-271.
Wang, W., Tang, J., & Wei, F. (2020). Updated understanding of the outbreak of 2019 novel coronavirus (SARS-CoV-2) in Wuhan, China. Journal of Medical Virology, 92 (4), 441-447.
Zhan, L. et al. (2020). Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors. Science, eabb3405.
Zhang, W. (2020). The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China. Clinical Immunology, 214, e108393.
Downloads
Published
Issue
Section
License
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
